TOP2A Promotes Lung Adenocarcinoma Cells' Malignant Progression and Predicts Poor Prognosis in Lung Adenocarcinoma.

Kou, Fan; Sun, Houfang; Wu, Lei; Li, Baihui; Zhang, Bailu; Wang, Xuezhou; Yang, Lili

Kou, Fan; Sun, Houfang; Wu, Lei; Li, Baihui; Zhang, Bailu; Wang, Xuezhou; Yang, Lili.

Afiliação

Kou F; Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Sun H; National Clinical Research Center for Cancer, Tianjin, China.
Wu L; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
Li B; Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Zhang B; Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Wang X; Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Yang L; National Clinical Research Center for Cancer, Tianjin, China.

J Cancer ; 11(9): 2496-2508, 2020.

Article em En | MEDLINE | ID: mdl-32201520

Palavras-chave

lung cancer; p53 pathway; topoisomerase IIA; tumorigenesis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Cancer Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google